ClinicalTrials.gg
CompletedNCT03108664Updated Feb 15, 2019

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

A Phase 3 interventional study of SYL1001 ophthalmic solution and Vehicle opthalmic solution in Dry Eye Disease, sponsored by Sylentis, S.A.. Completed at 40 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Enrollment
4th of 41
330 · median 60
Started
2017
with 2 others
Phase 3
6 of 44
none open now
Registered
9th of 44
by date
Lead sponsor
5 of 44
Sylentis, S.A.

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 4th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 in phase 3, and was the 9th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether SYL1001 ophthalmic solution is safe and effective in the treatment of signs and symptoms of Dry Eye Disease.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

Keywords

  • SYL1001
  • siRNA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both genders
  • ≥ 18 years old
  • Give written to participate in the study after having been informed of the study design, objectives and possible derived risks
  • Common symptoms of persistent, daily, moderate to severe dry eye lasting more than six months.
  • Use of artificial tears
  • VAS scale for eye discomfort/pain between 30 - 80
  • CFS ≥ 2 and ≤ 4 on the Oxford scale
  • TBUT \< 10 seconds
  • Hyperemia score ≥ 1 (McMonnies scale)
  • Schirmer's test without anesthesia ≥ 2 and \< 10 mm/5min in the eye
  • Corrected visual acuity ≥ 0.7 logMAR

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females or those with a positive pregnancy test.
  • Females of who will not use a medically acceptable method from selection and during the whole study.
  • Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal distress, hypertension, or infectious acute processes.
  • Past history of a chronic o recurring condition that could interfere with study according to the investigator's judgement.
  • Concomitant use of other drugs with analgesic activity by any route of administration at the enrolment period.
  • Changes in any ocular and/or systemic concomitant medication one month prior to the study commencement and during the study development.
  • Changes on the preestablished artificial tears dosage 15 days prior to the study commencement and during the study development.
  • Cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen during the 6 months prior to enrolment.
  • Previous history of drug .
  • Use of contact lenses
  • Case history of drug or alcohol abuse or dependence.
  • Relevant abnormal laboratory results as judged by the investigator
  • Previous refractive surgery
  • Participation in a clinical trial within 2 months before the enrolment visit
  • Relevant ocular pathology judged by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    11.25 mg/mL SYL1001 ophthalmic solution

    1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d

    Drug: SYL1001 ophthalmic solution

  • Experimental
    Vehicle ophthalmic solution

    1 drop of vehicle ophthalmic solution in the affected eye(s) q.d

    Drug: Vehicle opthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Visual Analogue Scale (VAS) scores for eye discomfort/pain as a measurement of SYL1001 effect versus vehicle

    Time frame: 28 days

  2. Change from baseline in Corneal Fluorescein Staining (CFS) total scores obtained on the Oxford scale as a measurement of SYL1001 effect versus vehicle

    Time frame: 28 days

  3. Change from baseline in conjunctival hyperaemia scores based on the McMonnies scale as a measurement of SYL1001 effect versus vehicle

    Time frame: 28 days

Secondary outcomes

  1. Assessment of Adverse Events Appearance as a measure of SYL1001 tolerability

    Time frame: 28 days

07

Study locations

40 sites
  • Eye Clinic Dr. Krista Turman
    Tallinn, 13419, Estonia
  • East Tallin Central Hospital
    Tallin, 10138, Estonia
  • Tartu University Hospital
    Tartu, 50406, Estonia
  • Augenzentrum Nord-West
    Ahaus, 48683, Germany
  • Universitäts-Augenklinik Düsseldorf
    Dusseldorf, 40225, Germany
  • Universitätsklinikum Freiburg
    Freiburg, Germany
  • Universitätsklinikum des Saarlandes
    Homburg, Germany
  • Klinik für Augenheilkunde Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
  • Uniklinik Köln Zentrum für Augenheilkunde
    Köln, Germany
  • Universitätsklinikum Leipzig AöR Klinik und Poliklinik für Augenheilkunde
    Leipzig, Germany
  • Augenklinik der Ludwig-Maximilian Universität München
    Munchen, 80336, Germany
  • AOU Careggi
    Firenze, Italy
  • Ospedale San Giuseppe
    Milan, Italy
  • Farmacia Azienda Ospedaliera di Padova
    Padova, Italy
  • A.O.U. Pisana
    Pisa, Italy
  • Hospital de Braga
    Braga, 4710-243, Portugal
  • Centro Hospitalar e Universitário de Coimbra
    Coimbra, Portugal
  • Hospital Lusiadas Lisboa
    Lisboa, 1500-461, Portugal
  • Bellet s.r.o
    Martin, 03601, Slovakia
  • Oftalmologická ambulancia
    Trenčín, 911 01, Slovakia
  • Fakultná nemocnica Trenčín,
    Trenčín, 911 71, Slovakia
  • Optomedic s.r.o
    Štúrovo, 943 01, Slovakia
  • OPHTHAMED, s.r.o.,
    Žilina, 01 001, Slovakia
  • VIKOM s.r.o
    Žilina, 010 08, Slovakia
  • Fakultná nemocnica s poliklinikou Žilina
    Žilina, 012 07, Slovakia
  • Instituto Oftalmológico Fernández Vega
    Oviedo, Asturias 33012, Spain
  • Hospital Universitario Príncipe de Asturias
    Alcala de Henares, Madrid 28805, Spain
  • Clínica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Institut Català de la Retina
    Barcelona, 08017, Spain
  • Instituto de Oftalmología del Hospital Clínic de Barcelona Casa de la Maternitat
    Barcelona, 08028, Spain
  • Instituto de Microcirugía Ocular (IMO)
    Barcelona, 08035, Spain
  • Centro de Oftalmología Barraquer
    Barcelona, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28043, Spain
  • Hospital Universitario la Paz
    Madrid, 28046, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • FISABIO Oftalmología Médica (FOM)
    Valencia, 46017, Spain
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Spain
  • Hospital Provincial Nuestra Señora de Gracia
    Zaragoza, 50004, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Oct 2018, 16 months.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 16 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2017
First posted
Apr 11, 2017
StartActual
May 18, 2017
Primary completionActual
Oct 16, 2018
CompletionActual
Nov 16, 2018
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03108664
Lead sponsor
Sylentis, S.A.
Responsible party
Sponsor
First posted
Apr 11, 2017
Start date
May 18, 2017
Primary completion
Oct 16, 2018
Completion
Nov 16, 2018
Last update
Feb 15, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tivanisiran

Start the discussion